$5.06 Billion is the total value of Baker Brothers Advisors's 75 reported holdings in Q2 2013. The portfolio turnover from Q1 2013 to Q2 2013 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PCYC | New | Pharmacyclics Inc. | $855,982,000 | – | 10,771,138 | +100.0% | 16.93% | – |
| SGEN | New | Seattle Genetics Inc. | $607,900,000 | – | 19,322,947 | +100.0% | 12.02% | – |
| GHDX | New | Genomic Health Inc. | $432,868,000 | – | 13,650,835 | +100.0% | 8.56% | – |
| New | Incyte Genomics Notes 4.75% 10/1/2015conv bonds | $401,692,000 | – | 157,758,000 | +100.0% | 7.94% | – | |
| GEVA | New | Synageva Biopharma Corp. | $387,189,000 | – | 9,223,182 | +100.0% | 7.66% | – |
| ACAD | New | Acadia Pharmaceuticals Inc. | $362,186,000 | – | 19,955,126 | +100.0% | 7.16% | – |
| New | Salix 2.75% 5/15/15conv bonds | $334,029,000 | – | 219,440,000 | +100.0% | 6.61% | – | |
| INCY | New | Incyte Corp. | $325,832,000 | – | 14,810,559 | +100.0% | 6.44% | – |
| VPHM | New | Viropharma Inc. | $244,344,000 | – | 8,528,603 | +100.0% | 4.83% | – |
| New | Auxilium 1.5% 7/15/2018conv bonds | $88,098,000 | – | 91,590,000 | +100.0% | 1.74% | – | |
| XOMA | New | Xoma Corp. | $73,597,000 | – | 20,274,581 | +100.0% | 1.46% | – |
| GILD | New | Gilead Sciences Inc. | $63,872,000 | – | 1,245,800 | +100.0% | 1.26% | – |
| New | Biomarin Pharmaceuticals Notes 1.875% 4/23/2017conv bonds | $63,217,000 | – | 22,898,000 | +100.0% | 1.25% | – | |
| AEGR | New | Aegerion Pharmaceuticals | $58,548,000 | – | 924,343 | +100.0% | 1.16% | – |
| HALO | New | Halozyme Therapeutics Inc. | $52,098,000 | – | 6,553,150 | +100.0% | 1.03% | – |
| RPRX | New | Repros Therapeutics | $51,266,000 | – | 2,778,654 | +100.0% | 1.01% | – |
| New | Medivation 2.625% 4/1/17conv bonds | $50,054,000 | – | 39,500,000 | +100.0% | 0.99% | – | |
| New | Gilead 1.625% 5/1/16conv bonds | $48,664,000 | – | 21,500,000 | +100.0% | 0.96% | – | |
| New | Intermune Inc Notes 2.5% 12/15/17conv bonds | $43,896,000 | – | 41,000,000 | +100.0% | 0.87% | – | |
| BMRN | New | Biomarin Pharmaceuticals | $43,662,000 | – | 783,311 | +100.0% | 0.86% | – |
| CERS | New | Cerus | $37,372,000 | – | 8,455,306 | +100.0% | 0.74% | – |
| CLVS | New | Clovis Oncology | $35,172,000 | – | 525,113 | +100.0% | 0.70% | – |
| VNDA | New | Vanda Pharmaceuticals, Inc. | $32,047,000 | – | 3,966,179 | +100.0% | 0.63% | – |
| ARIA | New | Ariad Pharmaceuticals Inc. | $25,361,000 | – | 1,450,000 | +100.0% | 0.50% | – |
| STML | New | Stemline Therapeutics Inc. | $21,456,000 | – | 900,000 | +100.0% | 0.42% | – |
| ICPT | New | Intercept Pharmaceuticals, Inc. | $20,754,000 | – | 462,847 | +100.0% | 0.41% | – |
| MDVN | New | Medivation Inc. | $19,598,000 | – | 398,331 | +100.0% | 0.39% | – |
| PGNX | New | Progenics Pharmaceuticals, Inc. | $18,732,000 | – | 4,200,000 | +100.0% | 0.37% | – |
| DSCI | New | Derma Sciences | $18,141,000 | – | 1,358,857 | +100.0% | 0.36% | – |
| New | Intermune Inc Notes 5% 3/1/15conv bonds | $17,756,000 | – | 16,860,000 | +100.0% | 0.35% | – | |
| INFI | New | Infinity Pharmaceuticals Inc. | $16,458,000 | – | 1,016,433 | +100.0% | 0.33% | – |
| AVNR | New | Avanir Pharmaceuticals | $16,462,000 | – | 3,578,591 | +100.0% | 0.33% | – |
| QCOR | New | Questcor Pharmaceuticals, Inc. | $14,352,000 | – | 315,846 | +100.0% | 0.28% | – |
| SGYPQ | New | Synergy Pharmaceuticals | $11,268,000 | – | 2,608,271 | +100.0% | 0.22% | – |
| CHTP | New | Chelsea Therapeutics | $10,984,000 | – | 4,775,787 | +100.0% | 0.22% | – |
| PTLA | New | Portola Pharmaceuticals, Inc. | $9,826,000 | – | 399,914 | +100.0% | 0.19% | – |
| INSM | New | Insmed Inc. | $9,518,000 | – | 795,803 | +100.0% | 0.19% | – |
| IRWD | New | Ironwood Pharmaceuticals | $9,157,000 | – | 922,160 | +100.0% | 0.18% | – |
| BCRX | New | Biocryst Pharmaceuticals Inc. | $8,623,000 | – | 5,563,615 | +100.0% | 0.17% | – |
| THLD | New | Threshold Pharma | $8,390,000 | – | 1,595,048 | +100.0% | 0.17% | – |
| SNTA | New | Synta Pharmaceuticals | $6,981,000 | – | 1,399,040 | +100.0% | 0.14% | – |
| ARRY | New | Array Biopharma Inc. | $6,810,000 | – | 1,500,000 | +100.0% | 0.14% | – |
| QLTI | New | QLT, Inc. | $6,742,000 | – | 1,535,863 | +100.0% | 0.13% | – |
| ISIS | New | Isis Pharmaceuticals | $6,638,000 | – | 247,036 | +100.0% | 0.13% | – |
| CCXI | New | Chemocentryx Inc. | $5,303,000 | – | 375,000 | +100.0% | 0.10% | – |
| AMBI | New | Ambit Biosciences Corp. | $5,236,000 | – | 747,962 | +100.0% | 0.10% | – |
| XNPT | New | Xenoport | $5,119,000 | – | 1,034,112 | +100.0% | 0.10% | – |
| New | Anacor Pharmaceuticals | $4,899,000 | – | 876,463 | +100.0% | 0.10% | – | |
| PRTA | New | Prothena Corp. PLC | $4,772,000 | – | 369,650 | +100.0% | 0.09% | – |
| KYTH | New | Kythera Biopharmaceuticals | $4,463,000 | – | 165,000 | +100.0% | 0.09% | – |
| ACHN | New | Achillion | $3,722,000 | – | 455,000 | +100.0% | 0.07% | – |
| MEIP | New | MEI Pharma, Inc. | $3,677,000 | – | 515,612 | +100.0% | 0.07% | – |
| PBYI | New | Puma Biotechnology | $3,697,000 | – | 83,333 | +100.0% | 0.07% | – |
| BDSI | New | BioDelivery Sciences Intl. Inc. | $3,656,000 | – | 900,505 | +100.0% | 0.07% | – |
| ZGNX | New | Zogenix, Inc. | $3,422,000 | – | 2,001,000 | +100.0% | 0.07% | – |
| SLXP | New | Salix Pharmaceuticals, Inc. | $3,015,000 | – | 45,571 | +100.0% | 0.06% | – |
| IDRA | New | Idera Pharmaceuticals Inc. | $2,948,000 | – | 4,500,000 | +100.0% | 0.06% | – |
| VTUS | New | Ventrus Biosciences, Inc. | $2,918,000 | – | 1,215,840 | +100.0% | 0.06% | – |
| LGND | New | Ligand Pharmaceuticals Inc.class b | $2,745,000 | – | 73,400 | +100.0% | 0.05% | – |
| DSCO | New | Discovery Laboratories Inc. | $2,308,000 | – | 1,518,617 | +100.0% | 0.05% | – |
| ENTA | New | Enanta Pharmaceuticals | $2,214,000 | – | 125,000 | +100.0% | 0.04% | – |
| CYTR | New | Cytrx Corp. | $2,000,000 | – | 1,000,000 | +100.0% | 0.04% | – |
| ARQL | New | Arqule Inc. | $2,041,000 | – | 879,805 | +100.0% | 0.04% | – |
| RCPT | New | Receptos Inc. | $1,989,000 | – | 100,000 | +100.0% | 0.04% | – |
| GERN | New | Geron Corp. | $1,500,000 | – | 1,000,000 | +100.0% | 0.03% | – |
| FOLD | New | Amicus Therapeutics | $1,200,000 | – | 515,072 | +100.0% | 0.02% | – |
| TSRO | New | Tesaro Inc. | $1,022,000 | – | 31,218 | +100.0% | 0.02% | – |
| OSUR | New | Orasure Technologies Inc. | $945,000 | – | 243,467 | +100.0% | 0.02% | – |
| BIOD | New | Biodel Inc. | $961,000 | – | 229,885 | +100.0% | 0.02% | – |
| LPTN | New | Lpath Inc. | $880,000 | – | 200,000 | +100.0% | 0.02% | – |
| ZIOP | New | Ziopharm Oncology Inc. | $536,000 | – | 254,199 | +100.0% | 0.01% | – |
| EPZM | New | Epizyme Inc. | $563,000 | – | 20,000 | +100.0% | 0.01% | – |
| CBST | New | Cubist Pharmaceuticals Inc. | $241,000 | – | 5,000 | +100.0% | 0.01% | – |
| CYCCP | New | Cyclacel Pharmaceuticals Pfd. Conv. Ex 6%pfd conv ex | $151,000 | – | 20,979 | +100.0% | 0.00% | – |
| ARDM | New | Aradigm Corp. | $16,000 | – | 100,000 | +100.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2013-08-14
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.